India, April 28 -- Biotechnology company Revvity, Inc. (RVTY), while reporting higher first-quarter results above market estimates, on Monday reaffirmed its fiscal 2025 adjusted earnings forecast and raised total revenue outlook.
In pre-market activity on the NYSE, Revvity shares were gaining around 4.7 percent to trade at $98.73.
For the full year 2025, the company continues to expect adjusted earnings in a range of $4.90 to $5.00 per share.
Revenue is now expected in a range of $2.83 billion to $2.87 billion, higher than previously expected $2.80 billion and $2.85 billion, to reflect recent changes in foreign currency.
The company further reaffirmed its organic growth guidance of 3 percent to 5 percent.
On average, analysts polled ex...